Actinium Pharmaceuticals
ATNM
27 hedge funds and large institutions have $5.66M invested in Actinium Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 7 closing their positions.
528% more call options, than puts
Call options by funds: $182K | Put options by funds: $29K
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
9% more capital invested
Capital invested by funds: $5.2M → $5.66M (+$456K)
0.02% more ownership
Funds ownership: 0.21% → 0.23% (+0.02%)
10% less funds holding
Funds holding: 30 → 27 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$473K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$259K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$87.7K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$45.5K |
| 5 |
Morgan Stanley
New York
|
+$34.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$51K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$31.7K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$24K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
26
Advisor Group
Phoenix,
Arizona
| $3K | +$3.91K | +70 | New |
|
|
VKH
27
Virtu KCG Holdings
New York
| – | -$51K | -847 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$39K | -657 | Closed |
|
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$31.7K | -568 | -99% |
|
|
OAM
30
Oxford Asset Management
Oxford,
United Kingdom
| – | -$24K | -404 | Closed |
|
31
Simplex Trading
Chicago,
Illinois
| – | -$4.91K | -88 | Closed |
|
|
AIG
32
American International Group
New York
| – | -$4K | -70 | Closed |
|
ATNM Hedge Fund Activity: Q2 2016 in Review
27 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2016, worth a combined $5.66M — up 8.8% from $5.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATNM and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $473K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $51K sold.
- 27 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2016, down from 30 in Q1 2016.
- Funds reported $5.66M of Actinium Pharmaceuticals stock for Q2 2016, up 8.8% quarter-over-quarter.
- 4 funds opened new Actinium Pharmaceuticals positions in Q2 2016 and 7 closed out, a net change of -3 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2016 was Vanguard Group, an estimated $473K added.
- The largest Actinium Pharmaceuticals seller in Q2 2016 was Virtu KCG Holdings, an estimated $51K sold.
Based on aggregated 13F filings for Q2 2016.